Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner; Andrew H. Wei; Frederick R. Appelbaum; Charles Craddock; Courtney D. DiNardo; Hervé Dombret; Benjamin L. Ebert; Pierre Fenaux; Lucy A. Godley; Robert P. Hasserjian; Richard A. Larson; Ross L. Levine; Yasushi Miyazaki; Dietger Niederwieser; Gert Ossenkoppele; Christoph Röllig; Jorge Sierra; Eytan M. Stein; Martin S. Tallman; Hwei Fang Tien; Jianxiang Wang; Agnieszka Wierzbowska; Bob Löwenberg

doi:10.1182/blood.2022016867

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, Charles Craddock, Courtney D. DiNardo, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Lucy A. Godley, Robert P. Hasserjian, Richard A. Larson, Ross L. Levine, Yasushi Miyazaki, Dietger Niederwieser, Gert Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M. Stein, Martin S. Tallman, Hwei Fang TienJianxiang Wang, Agnieszka Wierzbowska, Bob Löwenberg

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

1462 Scopus citations

Abstract

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

Original language	English (US)
Pages (from-to)	1345-1377
Number of pages	33
Journal	Blood
Volume	140
Issue number	12
DOIs	https://doi.org/10.1182/blood.2022016867
State	Published - Sep 22 2022

Funding

The authors gratefully acknowledge R\u00FCdiger Hehlmann for his continuous generous support of these recommendations on behalf of the European LeukemiaNet and Partrycja Gradowska, Axel Benner, Maral Saadati, and Julia Krzykalla for reviewing the sections \u201CResponse criteria\u201D and \u201COutcome measures.\u201D, H. D\u00F6hner is supported by SFB 1074 \u201CExperimental models and clinical translation in leukemia\u201D funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award. Clara Bloomfield, Elihu Estey and Francesco Lo-Coco have died since the publication of the 2017 ELN AML Recommendation edition. The authors acknowledge the impressive seminal contributions that Clara Bloomfield, Elihu Estey, and Francesco Lo-Coco made throughout many years to improve the treatment of AML and advance our understanding of the pathobiology of the disease. They were founding coauthors of the ELN AML Recommendation editions that first appeared in 2010 and (pro)actively participated with a high level of commitment in this endeavor. Each one in their own unique way contributed their invaluable clinical expertise, knowledge, and scientific rigor and were instrumental in establishing these recommendations as a widely accepted standard of reference. H. D\u00F6hner is supported by SFB 1074 \u201CExperimental models and clinical translation in leukemia\u201D funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award.

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2022016867

Cite this

Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., ... Löwenberg, B. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12), 1345-1377. https://doi.org/10.1182/blood.2022016867

@article{14f5f9ec1d2540dcb7c269fdc8489c72,

title = "Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN",

abstract = "The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.",

author = "Hartmut D{\"o}hner and Wei, {Andrew H.} and Appelbaum, {Frederick R.} and Charles Craddock and DiNardo, {Courtney D.} and Herv{\'e} Dombret and Ebert, {Benjamin L.} and Pierre Fenaux and Godley, {Lucy A.} and Hasserjian, {Robert P.} and Larson, {Richard A.} and Levine, {Ross L.} and Yasushi Miyazaki and Dietger Niederwieser and Gert Ossenkoppele and Christoph R{\"o}llig and Jorge Sierra and Stein, {Eytan M.} and Tallman, {Martin S.} and Tien, {Hwei Fang} and Jianxiang Wang and Agnieszka Wierzbowska and Bob L{\"o}wenberg",

note = "Funding Information: H. D{\"o}hner is supported by SFB 1074 “Experimental models and clinical translation in leukemia” funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award. Funding Information: The authors gratefully acknowledge R{\"u}diger Hehlmann for his continuous generous support of these recommendations on behalf of the European LeukemiaNet and Partrycja Gradowska, Axel Benner, Maral Saadati, and Julia Krzykalla for reviewing the sections “Response criteria” and “Outcome measures.”, H. D{\"o}hner is supported by SFB 1074 “Experimental models and clinical translation in leukemia” funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award. Clara Bloomfield, Elihu Estey and Francesco Lo-Coco have died since the publication of the 2017 ELN AML Recommendation edition. The authors acknowledge the impressive seminal contributions that Clara Bloomfield, Elihu Estey, and Francesco Lo-Coco made throughout many years to improve the treatment of AML and advance our understanding of the pathobiology of the disease. They were founding coauthors of the ELN AML Recommendation editions that first appeared in 2010 and (pro)actively participated with a high level of commitment in this endeavor. Each one in their own unique way contributed their invaluable clinical expertise, knowledge, and scientific rigor and were instrumental in establishing these recommendations as a widely accepted standard of reference. Publisher Copyright: {\textcopyright} 2022 American Society of Hematology",

year = "2022",

month = sep,

day = "22",

doi = "10.1182/blood.2022016867",

language = "English (US)",

volume = "140",

pages = "1345--1377",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "12",

}

Döhner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, J, Wierzbowska, A & Löwenberg, B 2022, 'Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN', Blood, vol. 140, no. 12, pp. 1345-1377. https://doi.org/10.1182/blood.2022016867

TY - JOUR

T1 - Diagnosis and management of AML in adults

T2 - 2022 recommendations from an international expert panel on behalf of the ELN

AU - Döhner, Hartmut

AU - Wei, Andrew H.

AU - Appelbaum, Frederick R.

AU - Craddock, Charles

AU - DiNardo, Courtney D.

AU - Dombret, Hervé

AU - Ebert, Benjamin L.

AU - Fenaux, Pierre

AU - Godley, Lucy A.

AU - Hasserjian, Robert P.

AU - Larson, Richard A.

AU - Levine, Ross L.

AU - Miyazaki, Yasushi

AU - Niederwieser, Dietger

AU - Ossenkoppele, Gert

AU - Röllig, Christoph

AU - Sierra, Jorge

AU - Stein, Eytan M.

AU - Tallman, Martin S.

AU - Tien, Hwei Fang

AU - Wang, Jianxiang

AU - Wierzbowska, Agnieszka

AU - Löwenberg, Bob

N1 - Funding Information: H. Döhner is supported by SFB 1074 “Experimental models and clinical translation in leukemia” funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award. Funding Information: The authors gratefully acknowledge Rüdiger Hehlmann for his continuous generous support of these recommendations on behalf of the European LeukemiaNet and Partrycja Gradowska, Axel Benner, Maral Saadati, and Julia Krzykalla for reviewing the sections “Response criteria” and “Outcome measures.”, H. Döhner is supported by SFB 1074 “Experimental models and clinical translation in leukemia” funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award. Clara Bloomfield, Elihu Estey and Francesco Lo-Coco have died since the publication of the 2017 ELN AML Recommendation edition. The authors acknowledge the impressive seminal contributions that Clara Bloomfield, Elihu Estey, and Francesco Lo-Coco made throughout many years to improve the treatment of AML and advance our understanding of the pathobiology of the disease. They were founding coauthors of the ELN AML Recommendation editions that first appeared in 2010 and (pro)actively participated with a high level of commitment in this endeavor. Each one in their own unique way contributed their invaluable clinical expertise, knowledge, and scientific rigor and were instrumental in establishing these recommendations as a widely accepted standard of reference. Publisher Copyright: © 2022 American Society of Hematology

PY - 2022/9/22

Y1 - 2022/9/22

N2 - The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

AB - The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85135885465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135885465&partnerID=8YFLogxK

U2 - 10.1182/blood.2022016867

DO - 10.1182/blood.2022016867

M3 - Article

C2 - 35797463

AN - SCOPUS:85135885465

SN - 0006-4971

VL - 140

SP - 1345

EP - 1377

JO - Blood

JF - Blood

IS - 12

ER -

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this